Already Registered? Sign in to continue reading.

New to Pink Sheet? Request a free trial today!

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Clinical Trials

Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA

This article was originally published in The Pink Sheet Daily

13 Jun 2016
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Request a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Clinical Trials

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079502

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079502

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Finish creating your saved search alert after you sign in

Thanks, we've sent a link to reset your password

Forgot your password?

Enter the email address associated with your account and an email will be sent to you to reset your password.

Please enter a valid email address.

Unfortunately we've not been able to process this request.

Need help?

Email: clientservices@pharmamedtechbi.com
Phone: (US Toll-Free): +1 888-670-8900; (US Collect): +1 908-547-2200
Phone (UK & Europe): +44 (20) 337 73737
Phone (APAC): +61 2 8705 6907

Thanks, we've sent a link to reset your password

Forgot your password?

Enter the email address associated with your account and an email will be sent to you to reset your password.

Please enter a valid email address.

Unfortunately we've not been able to process this request.

Need help?

Email: clientservices@pharmamedtechbi.com
Phone: (US Toll-Free): +1 888-670-8900; (US Collect): +1 908-547-2200
Phone (UK & Europe): +44 (20) 337 73737
Phone (APAC): +61 2 8705 6907

Forgot your password?

Forgot your password?

Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA

News

Executive Summary

Forgot your password?

Related Content

Merck Partners With Korea’s Samsung Bioepis On Multiple Biosimilar Targets

Topics

Related Companies

You must sign in to use this functionality

Forgot your password?

Authentication.SignIn.HeadSignInHeader

Forgot your password?

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert

Forgot your password?

Forgot your password?